4D Molecular Therapeutics (FDMT) Stock Analysis & AI Equity Report
4D Molecular Therapeutics (FDMT) overview
4D Molecular Therapeutics (FDMT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 85.2m and operating profit of USD -160m; the year-end share price was 7.50 USD and market capitalisation was USD 432m. 4D Molecular Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get 4D Molecular Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About 4D Molecular Therapeutics
4D Molecular Therapeutics develops genetic medicines using its proprietary adeno-associated virus vector discovery and engineering platform. Its lead candidate, 4D-150, is in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, an inhaled gene therapy candidate for cystic fibrosis, and 4D-175, an investigational program for geographic atrophy.
Generate the 4D Molecular Therapeutics report
4D Molecular Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for 4D Molecular Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on 4D Molecular Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.